Literature DB >> 34179542

Influence of APOE locus on poor prognosis of COVID-19.

Juliana Carla Gomes Rodrigues1, Pablo Pinto1,2, Luciana Pereira Colares Leitão1, Lui Wallacy Morikawa Souza Vinagre1, Natasha Monte1, Marianne Rodrigues Fernandes1, André Salim Khayat1, Paulo Pimentel de Assumpção1, Ney Pereira Carneiro Dos Santos1, Sidney Emanuel Batista Dos Santos1,2.   

Abstract

The COVID-19 pandemic has infected over 25 million of people worldwide, 5% of whom evolved to death and, among of the active cases, more than 60 thousand are classified as critical or severe. Recent studies revealed that ApoE, a protein encoded by APOE gene, may increase the risk of severe COVID-19 cases. ApoE has been involved with prevention of tissue damage and promotion of adaptative immune response in the lungs. This study investigated frequencies distribution of alleles that alter the ApoE expression in lung tissues to trace a profile of these variants and associate them to COVID-19 clinical outcomes. Data about APOE expression levels was obtained from the Genotype-Tissue Expression Project and the allele frequencies of APOE variants was acquired from the populations included in the phase 3 release of the 1000 Genomes Project. A total of 128 variants showed a significant impact on the APOE expression in lung tissues (p < 0.0001). Linkage Disequilibrium analysis revealed that 98 variants were closely grouped into seven distinct haplotype blocks, of which six were composed of variants that significantly decrease APOE gene expression in the lungs. Most of the haplotypes with higher impact on APOE expression showed greater frequencies in Europeans and lower in Africans, which implies that European populations might be more susceptible to SARS-CoV-2 infection. The present study indicates a potential genetic contribution of APOE expression-modifying variants in modulating the prognosis of COVID-19.
© 2021 Published by Elsevier Ltd.

Entities:  

Keywords:  APOE; COVID-19; Lung; SARS-CoV-2; Susceptibility

Year:  2021        PMID: 34179542      PMCID: PMC8220252          DOI: 10.1016/j.heliyon.2021.e07379

Source DB:  PubMed          Journal:  Heliyon        ISSN: 2405-8440


Introduction

Apolipoprotein E (ApoE) is encoded by the APOE gene on chromosome 19 and has three common alleles, ε2, ε3, and ε4, which presents an extensive genetic diversity across ethnic populations. These allele frequencies vary widely (ε2, 5%–10 %; ε3, 65%–70 %; and ε4, 15%–20 %) [1]. The function of ApoE is to play a pivotal role in the transport, metabolism, and homeostasis of cholesterol and other lipids by serving as a ligand for low-density lipoprotein receptors (LDLRs) and heparan sulfate proteoglycans (HSPGs) (Martínez-Martínez et al., 2020; Hatters et al., 2006) [2,3]. Polymorphisms in APOE gene have been extensively described as major risk determinants of late-onset Alzheimer disease and cardiovascular disorders; in both conditions, the APOE∗ε4 allele confers an increased risk and the APOE∗ε2 allele confers a decreased risk in comparison with the common APOE∗ε3 allele [4, 5]. Additionally, compelling evidence has been demonstrating the ability of ApoE isoforms in modulating immune responses through both proinflammatory and anti-inflammatory cytokines, which is closely linked to a predisposition to autoimmune disorders and infections [6]. [7] Several studies have reported the association of ApoE isoforms with the life cycle, pathogenesis, and outcome of different viral infections, such as varicella-zoster and Epstein Barr viruses [8], herpes simplex virus [9], human immunodeficiency virus [10], hepatitis B virus [11], and hepatitis C virus [12]. Recently, a study conducted with the UK Biobank (UKB) community cohort, has revealed that ApoE, specifically the ε4∗ε4 genotype, increases the risk of severe Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [13]. This association was strongly significant, despite patients’ pre-existing comorbidities, such as dementia, cardiovascular disease, and type-2 diabetes. Although apoE is mainly expressed in the liver, it is also expressed by alveolar macrophages, type I and type II alveolar epithelial cells, and pulmonary artery smooth cells in the lung (Yao et al. 2016; Kockx, Traini, and Kritharides 2018) [14,15]. So, a possible reason for the relation between COVID-19 severity and APOE variants is that APOE∗ε4 might moderate macrophage pro-/anti-inflammatory phenotype in the lungs, which could drive to more extensive tissue damage. ApoE has been demonstrated to be a key protein to maintain normal lung homeostasis. To exert this role, ApoE acts controlling hypercholesterolemia (Figure 1), which prevents systemic inflammation and oxidative stress that may lead to pathological lung and vascular remodeling changes [15]. Also, this protein still augments adaptive immunity and host defense in the lungs through the mediation of the LDLR-dependent internalization of mycobacterial lipid antigens by antigen-presenting cells [15].
Figure 1

Modulation of lipid transport in the lung by apolipoprotein E (ApoE). (1) Exogenous pathway for apoE-mediated presentation of lipid antigens. ApoE facilitates the low-density lipoprotein receptors (LDLRs) internalization of mycobacterial lipid antigens for presentation by antigen-presenting cells; (2) ApoE mediates the cellular uptake of cholesterol, phospholipids, and triglycerides in lipoprotein particles, interacting with low-density lipoprotein receptors (LDLRs) located on the cell surface; (3) LDLRs are internalized in cells within the endocytic vesicles lined by clathrin proteins, which assist in the receptor-mediated endocytosis process. This image has been designed using resources from Flaticon.com.

Modulation of lipid transport in the lung by apolipoprotein E (ApoE). (1) Exogenous pathway for apoE-mediated presentation of lipid antigens. ApoE facilitates the low-density lipoprotein receptors (LDLRs) internalization of mycobacterial lipid antigens for presentation by antigen-presenting cells; (2) ApoE mediates the cellular uptake of cholesterol, phospholipids, and triglycerides in lipoprotein particles, interacting with low-density lipoprotein receptors (LDLRs) located on the cell surface; (3) LDLRs are internalized in cells within the endocytic vesicles lined by clathrin proteins, which assist in the receptor-mediated endocytosis process. This image has been designed using resources from Flaticon.com. The objective of this study is to investigate the frequency distribution of alleles responsible for altering gene expression of APOE in lung tissues to trace a profile of these variants and link them to poor clinical outcomes of COVID-19 patients worldwide. Since APOE expression has been linked to the prevention of tissue damage and promotion of adaptative immune response in the lungs, our analyses focused on the decreased expression of APOE in lung tissues.

Material and methods

All data concerning expression levels of APOE variants in lung tissues (means of expression, p-values, and expression quantitative trait loci [eQTL]) was obtained from the Genotype-Tissue Expression (GTEx) project (available at: https://www.gtexportal.org). The GTEx project is a centralized data source for information on inherited genetic variation and gene expression in 54 non-diseased tissue sites across nearly 1000 healthy individuals. Detailed information regarding the methodological procedures for the GTEx project have been previously described [16, 17]. Data regarding allele frequencies of the APOE variants evaluated here was from the populations included in the phase 3 release of the1000 Genomes Project (available at http://www.1000genomes.org) [18]. These data included populations of African (AFR), Admixed American (AMR), East Asian (EAS), European (EUR), and South Asian (SAS) descent. Linkage Disequilibrium (LD) was estimated and the haplotype blocks were compiled using the package “LDlinkR: An R Package for Calculating Linkage Disequilibrium” [19]. The cutoff for haplotype variants frequency was 0.5%. Details on haplotype blocks formation, such as the group of polymorphisms for each haplotype block, are shown in Supplementary Data. The differences in gene expression among the haplotype blocks were evaluated by a one-way Analysis of Variance (ANOVA), and the significance of the difference between the most divergent blocks was determined by Tukey's HSD test. All analyses were run in RStudio v.3.5.1, using the “multcompView” package, 157 v.0.1–8 [20].

Results

A total of 128 variants has a significant impact on the APOE expression in lung tissues. These mutations are listed in Table 1, which also shows which allele decreases the gene expression and the distribution of its allelic frequencies in the Africa, America, East Asia, Europe, and South Asia populations of the 1000 Genomes Project Database (Table 1).
Table 1

Characteristics of variants that have a significant impact on the APOE expression in lung tissues and their allele distribution in world populations.

Variant IdP-valueNESawt/wtwt/varvar/varAllelebAFRAMREASEURSAS
rs351365759.3e-100.27-0.058330.082680.2858C0.18530.20170.10910.23760.2546
rs730456913.1e-170.31-0.20550.058330.5972G0.3260.41350.55260.3290.3241
rs348100286.4e-120.24-0.37280.051030.2503A0.63990.71610.72920.4920.6288
rs129763953.2e-120.25-0.42550.048600.2780G0.80110.73490.72720.4920.6299
rs340410513.1e-180.32-0.21040.055890.6383T0.3290.4150.55750.3290.3272
rs353362433.1e-180.32-0.21040.055890.6383A0.32680.4150.55360.330.3231
rs129776044.6e-120.24-0.37280.048600.2579C0.63990.71610.72820.4920.6309
rs104130964.4e-100.23-0.16840.026720.2907G0.63920.71610.72820.49110.6329
rs730456965.4e-180.32-0.16850.026720.2907G0.30640.41210.55360.3290.3231
rs598594105.5e-180.31-0.20550.051030.6178A0.31320.41640.55360.3310.3231
rs1118097141.1e-180.31-0.20550.051030.5972T0.30180.41790.55360.3310.3221
rs1116068399.1e-180.31-0.21540.070500.5684A0.2920.41350.54660.3280.3221
rs1127845349.1e-180.31-0.22290.077800.5684G0.29050.41350.55360.3310.3231
rs2000241669.1e-180.31-0.21540.070500.5684TCTC0.29050.41210.55260.3310.3221
rs48037736.1e-120.24-0.40160.051030.2907A0.72690.72480.72720.4920.6329
rs127211111.3e-170.32-0.20550.070500.5627C0.24580.40920.55360.3310.3231
rs51575.7e-120.25-0.40950.014570.3059T0.80110.73630.72720.49110.6329
rs11328993.2e-120.25-0.46290.043730.2983T0.73070.72480.72620.4980.6391
rs51673.5e-190.32-0.27040.038870.5856T0.45690.45530.57240.36680.3415
rs22889127.6e-110.23-0.39370.012140.3212C0.76320.72910.67460.48610.636
rs22889111.9e-100.22-0.39110.0097160.2983T0.77310.73490.67360.4930.6411
rs93046442.2e-110.24-0.37280.058330.2907C0.57190.58790.59230.44830.5941
rs93046466.7e-110.23-0.37280.034010.3366T0.6210.59940.59520.44830.5982
rs48037748.4e-110.23-0.35720.021860.3573A0.62180.59940.59820.44930.6022
rs48037751.1e-100.23-0.40160.0024290.3572T0.80330.73490.65870.49010.6411
rs72566841.5e-100.23-0.37280.029150.3573A0.62330.60230.59030.45130.5971
rs51201.1e-100.23-0.40160.0024290.3572T0.80330.73490.65580.49110.6421
rs48037764.1e-120.25-0.39370.0024290.4096T0.80180.73050.65580.49110.6431
rs1504489966.6e-130.27-0.18320.13150.5401G0.24660.38040.5030.29030.2618
rs11307426.6e-130.27-0.18320.13150.5401C0.24580.38040.5030.29030.2618
rs72574681.9e-100.23-0.37280.038870.3573C0.60440.59940.58830.45130.6012
rs72583451.9e-100.23-0.37280.038870.3573T0.60590.59940.58830.45130.6012
rs72574761.9e-100.23-0.37280.038870.3573C0.60590.59940.58830.45130.5992
rs127098894.7e-130.27-0.18070.12910.5401G0.23150.37750.5020.29030.2597
rs104232081.9e-100.23-0.37280.038870.3573G0.60590.59940.58830.45130.5992
rs104026421.9e-100.23-0.37280.038870.3573G0.60670.59940.58830.45130.5992
rs72469007.1e-110.23-0.37280.058330.2907G0.5620.58930.58630.45130.5951
rs110837521.9e-100.23-0.37280.038870.3573G0.60590.59940.58830.45130.5992
rs72481621.9e-100.23-0.37280.038870.3573T0.60590.59940.58830.45130.5992
rs72472277.1e-110.23-0.37280.058330.2907A0.56350.58930.58630.45130.5971
rs72475511.1e-100.23-0.40160.0024290.3572G0.80560.73490.65580.49110.6442
rs8921017.1e-110.23-0.37280.058330.2907G0.56280.58930.58430.45130.5961
rs72515011.0e-100.23-0.38850.043730.3573C0.60590.59940.58630.45130.5992
rs72515031.0e-100.23-0.38850.043730.3573C0.60590.59940.58630.45130.5992
rs124603461.9e-100.23-0.37280.038870.3573C0.60670.59940.58630.45130.5992
rs124603471.9e-100.23-0.37280.038870.3573C0.60670.59940.58630.45130.5992
rs72547231.9e-100.23-0.37280.038870.3573A0.59910.59940.58630.45030.5971
rs124603521.9e-100.23-0.37280.038870.3573C0.60670.59940.58630.45130.5992
rs1127571141.9e-100.23-0.37280.038870.3573TA0.60590.59940.58630.45130.5992
rs1397643221.9e-100.23-0.37280.038870.3573T0.60590.59940.58630.45130.5992
rs48037777.1e-110.23-0.37280.058330.2907G0.56280.58930.58430.45130.5961
rs48037781.0e-100.23-0.34690.029150.3780T0.60590.59940.58630.45030.5992
rs48037791.9e-100.23-0.37280.038870.3573T0.60590.59940.58630.45130.5992
rs48037801.9e-100.23-0.37280.038870.3573C0.60590.59940.58630.45130.5992
rs37606251.9e-100.23-0.37280.038870.3573G0.60590.59940.58630.45130.5992
rs37606261.9e-100.23-0.37280.038870.3573A0.60670.59940.58630.45130.5992
rs37606277.1e-110.23-0.37280.058330.2907T0.56280.58930.58430.45130.5961
rs37606281.9e-100.23-0.37280.038870.3573G0.60590.59940.58630.45130.5992
rs668678015.7e-110.23-0.37280.053460.3136C0.56510.58930.58430.45430.5961
rs72596791.0e-100.23-0.38850.043730.3573C0.60670.59940.58630.45430.6002
rs667713317.1e-110.23-0.37280.058330.2907G0.56350.58930.58330.45430.5961
rs730476431.3e-120.27-0.18320.13150.5401T0.24660.38180.5030.29520.274
rs72456111.6e-100.23-0.37280.029150.3573T0.60590.59940.58630.45130.5992
rs37606292.2e-100.22-0.37280.034010.3780A0.61040.60090.58730.45130.6002
rs22386822.0e-120.27-0.18320.13150.5401C0.23450.37460.5020.29130.2607
rs72524802.0e-120.27-0.18320.13150.5401C0.2360.37460.5020.29130.2607
rs48037811.3e-100.23-0.37280.038870.3859G0.61120.60230.58730.45330.6002
rs22393759.4e-110.23-0.38850.038870.3859T0.61120.60230.58730.45330.5992
rs2049051.3e-100.23-0.4016-0.0048580.3676G0.80480.73490.65670.49110.6431
rs18827523.1e-120.26-0.19060.13890.5457G0.26780.37750.5030.29920.2638
rs355660320.00000140.17-0.16100.038870.1586GA0.34110.55480.55850.41250.5143
rs81001202.1e-100.22-0.35720.034010.3573T0.60510.60230.58930.45230.6033
rs81002362.1e-100.22-0.35720.034010.3573T0.60510.60230.58730.45230.5951
rs1119972002.1e-100.22-0.35720.034010.3573T0.60510.60230.58730.45230.5951
rs1479014164.4e-100.31-0.077800.14630.5457C0.06050.18590.26590.1710.1789
rs1127044994.3e-120.26-0.18070.12420.5599G0.23150.37610.5020.30020.2638
rs1425349854.3e-120.26-0.18070.12420.5599TAACTC0.23150.37610.5020.30020.2638
rs104162610.00000190.17-0.16350.038870.2005C0.33590.55190.55850.40360.5143
rs1130732201.3e-100.23-0.35720.034010.3859A0.60210.59650.58630.44730.5951
rs118785971.4e-100.23-0.35720.029150.3937T0.61120.60090.58730.44330.5961
rs351933173.5e-10-0.220.3366-0.004858-0.3937T0.19590.26080.34330.5010.3599
rs48037831.4e-10-0.230.53450.1266-0.2503C0.48110.47120.42660.65310.6881
rs21420743.1e-120.26-0.18570.13890.5599A0.2360.37460.5020.29130.2638
rs1414087137.1e-12-0.230.52610.05589-0.2503A0.3290.45530.41170.64710.6524
rs116687583.1e-120.26-0.18570.13890.5599C0.2360.37460.5020.29130.2628
rs116658493.1e-120.26-0.18570.13890.5599T0.2360.37460.5020.29130.2628
rs116696093.1e-120.26-0.18570.13890.5599C0.2360.37460.5020.29130.2628
rs713522472.0e-10-0.220.2907-0.004858-0.3885T0.19440.26660.34230.51190.3569
rs2044826.4e-80.19-0.16590.012140.1906A0.26930.55190.58630.41850.5644
rs574657545.9e-120.28-0.16350.14130.5627C0.4750.25790.42560.22560.2935
rs169795951.9e-80.25-0.10710.22040.4361G0.2330.20750.26790.18290.2106
rs20756205.2e-120.26-0.18070.12660.5457A0.23450.37460.5020.30120.2638
rs568037104.3e-120.26-0.18070.12420.5599C0.2360.37460.5020.30120.2648
rs72534586.0e-120.26-0.18320.12910.5457C0.2360.37460.5020.30120.2648
rs72579161.4e-10-0.230.33660.002429-0.4016C0.19590.26950.34330.51490.3599
rs81110691.7e-160.29-0.28050.034010.5741A0.47810.42220.53080.3410.3446
rs557626175.2e-120.26-0.18070.12660.5457C0.2360.37460.5020.30120.2648
rs557788585.2e-120.26-0.18070.12660.5457G0.2360.37460.5020.30120.2648
rs2044746.9e-17-0.290.54570.01943-0.3263T0.29730.44520.38590.63020.6104
rs608763305.2e-120.26-0.18070.12660.5457C0.2360.37460.5020.30120.2597
rs110837555.2e-120.26-0.18070.12660.5457C0.2360.37460.5020.30120.2648
rs116727481.7e-160.29-0.28050.034010.5741A0.48110.42220.53080.3410.3456
rs37865053.6e-160.29-0.28050.043730.5741A0.47880.42220.52880.3410.3425
rs2044682.2e-16-0.290.56270.01457-0.3366C0.29880.44520.39980.62620.6104
rs2044671.4e-16-0.290.56840.02915-0.3469G0.27160.44380.39980.62620.6104
rs116691731.5e-10-0.220.33660.002429-0.3911A0.2610.27380.34330.51490.3589
rs9091342.8e-160.29-0.28050.038870.5856T0.48490.42070.53080.3410.3456
rs8752550.0000013-0.170.12910.07537-0.2154G0.42210.30980.3710.54470.4376
rs20756185.2e-120.26-0.18070.12660.5457G0.23680.37460.5020.30120.2648
rs20756191.3e-160.29-0.28050.038870.5856A0.48560.42070.53080.3410.3456
rs350802931.5e-110.25-0.18570.12910.5401T0.25110.38040.5020.30120.2648
rs572041684.3e-170.30-0.28050.058330.5856A0.43720.41070.52880.3410.3425
rs8921317.2e-120.25-0.18210.12910.5457C0.24580.37750.5020.30020.2628
rs730476947.2e-120.25-0.18320.12910.5457G0.24580.37750.5020.30020.2648
rs567849787.2e-170.30-0.27550.063190.5627T0.42740.41930.52980.340.3384
rs23768662.6e-100.31-0.080240.15360.5457C0.0590.18440.26690.1710.1687
rs23768673.1e-110.23-0.19060.082680.5345T0.43420.51870.57440.34890.3037
rs72516555.2e-120.26-0.18070.12660.5457C0.23520.37610.5020.30020.2577
rs355775635.2e-170.29-0.35200.029150.5674C0.72770.57060.59820.38270.3814
rs351940625.7e-70.39-0.019430.3469-C0.00230.03460.0010.05270.0031
rs346470541.7e-110.25-0.23290.14630.5599C0.39790.40060.50690.30220.2597
rs344495940.0000055-0.170.2005-0.02429-0.3885C0.14220.26660.2560.46220.3742
rs23768680.000028-0.160.1758-0.02429-0.3937A0.14520.24930.25890.44530.3497
rs129722220.000014-0.160.1169-0.01943-0.2154A0.31010.27950.26790.45920.3742
rs1505575660.000051-0.150.1857-0.04373-0.3937G0.0250.23630.26590.44430.3456
rs97490770.000051-0.150.2154-0.04373-0.3963G0.08850.24640.26090.45330.3497
rs116682850.000080-0.150.2154-0.04373-0.3728A0.08550.24640.25790.45330.3497
rs48037914.8e-100.26-0.16590.16590.5457G0.40540.33860.40970.25750.3661

wt/wt: wild homozygote; wt/var: heterozygote; var/var: variant homozygote.

Normalized effect size: defined as the slope of the linear regression and computed as the effect of the alternative allele (ALT) relative to the reference allele (REF) in the human genome reference.

Allele that causes the most decrease in Apoe expression in lungs.

Characteristics of variants that have a significant impact on the APOE expression in lung tissues and their allele distribution in world populations. wt/wt: wild homozygote; wt/var: heterozygote; var/var: variant homozygote. Normalized effect size: defined as the slope of the linear regression and computed as the effect of the alternative allele (ALT) relative to the reference allele (REF) in the human genome reference. Allele that causes the most decrease in Apoe expression in lungs. The Linkage Disequilibrium (LD) analysis was performed and revealed that 98 variants were closely grouped into seven distinct blocks (both D’ and r2 > 0.9). The blocks are divided into I-VII, of which six (I-VI) are composed of variants that significantly decrease APOE gene expression in the lungs (p < 10−10). The blocks are detailed in Table 2.
Table 2

LD blocks of variants that decrease APOE expression in lung tissues.

Haplotype Blocksa
Frequencies
IAFRAMREASEURSAS
Wild type0.65050.57490.43750.6660.6646
Mutant0.2330.39910.53770.32410.3098
I.1
I.2
I.3
I.4
I.5
I.6
I.70.031
I.80.0204
I.9
0.0159




II
AFR
AMR
EAS
EUR
SAS
Wild type0.18530.25940.26390.48310.34151
Mutant0.590.70750.66770.47910.6155
II.10.10060.0101
II.20.04390.0058
II.30.02870.0546
II.40.0136
II.50.0091
II.6
0.0068




III
AFR
AMR
EAS
EUR
SAS
Wild type0.37370.39770.40080.54870.3937
Mutant0.55140.58650.58040.44730.5859
III.10.03930.0086
III.20.0089
III.30.0113
III.40.0076
III.5
0.0053




IV
AFR
AMR
EAS
EUR
SAS
Wild type0.384339630.41070.54370.3875
Mutant0.555258790.58230.43940.59
IV.1
IV.20.0082
IV.30.03330.0058
IV.40.0083
IV.5
IV.6





V
AFR
AMR
EAS
EUR
SAS
Wild type
Mutant0.00580.006
V.10.80110.72330.64880.48210.6329
V.20.19140.25650.33230.4950.3476
V.3
V.40.006
V.50.0089
V.6


0.0089


VI
AFR
AMR
EAS
EUR
SAS
Wild type0.68680.60230.49210.69280.7198
Mutant0.22240.37180.4990.27830.2434
VI.10.01210.0050.0133
VI.20.0061
VI.30.0051
VI.40.0099
VI.50.0089
VI.60.0058
VI.70.0318
VI.80.0151
VI.90.0098
VI.10





VII
AFR
AMR
EAS
EUR
SAS
Wild type0.56280.69450.72520.52980.6176
Mutant0.02420.2320.23810.44230.3395
VII.10.0130.01390.0245
VII.20.005
VII.30.0089
VII.40.0079
VII.50.0069
VII.60.22090.0303
VII.70.10740.0144
VII.80.0058
VII.90.0582
VII.100.0113
VII.110.0061

Haplotype frequency is lower than 0.5%.

Further details about haplotype blocks are available in the supplementary data.

LD blocks of variants that decrease APOE expression in lung tissues. Haplotype frequency is lower than 0.5%. Further details about haplotype blocks are available in the supplementary data. Linkage disequilibrium block I is formed by the following variants (with the allele responsible for the decrease of APOE expression in the lungs: rs73045691 (G), rs34041051 (T), rs35336243 (A), rs73045696 (G), rs59859410 (A), rs111809714 (T), rs111606839 (DEL), rs112784534 (G), rs200024166 (INS), and rs12721111 (C). This block contains 11 haplotypes, however only two have frequencies in all populations (the wild-type, responsible for all the variants that decreases APOE expression, and the mutant type). Three haplotypes are exclusively observed in AFR populations, and six were not identified in any of the 1000 Genomes populations. Additionally, the wild-type haplotype has the highest frequencies (varying of 44%–66%), where the EAS population shows the lowest frequency (44%) and the EUR shows the highest (66%). Linkage disequilibrium block II is composed of nine variants: rs34810028 (A), rs12976395 (G), rs12977604 (C), rs10413096 (G), rs4803773 (A), rs5157 (T), rs1132899 (T), rs2288912 (C), and rs2288911 (T). This block has eight haplotypes, all of them is observed in the AFR, four is seen in AMR, three have frequencies in EAS, and two are observed in both EUR and SAS populations. The wild type haplotype, which all variants are responsible for decreasing APOE expression in the lungs, is observed in all populations, with higher frequencies in the EUR (48%) and lower in the AFR (19%). Linkage disequilibrium block III includes 20 variants: rs9304644 (C), rs9304646 (T), rs4803774 (A), rs7256684 (A), rs7257468 (C), rs7258345 (T), rs7257476 (C), rs10423208 (G), rs10402642 (G), rs7246900 (G), rs11083752 (G), rs7248162 (T), rs7247227 (A), rs892101 (G), rs7251501 (C), rs7251503 (C), rs12460346 (C), rs12460347 (C), rs7254723 (A), and rs12460352 (C). This block has seven haplotypes, in which only two (the wild-type and mutant) are observed in all populations. The AFR population has the greater variability, with frequencies of six haplotypes. The haplotype that has the most impact on APOE expression is also the wild type, which shows higher frequencies in Europeans (55%) and lower in Africans (37%). Linkage disequilibrium block IV contains 21 variants: rs112757114 (INS), rs139764322 (T), rs4803777 (G), rs4803778 (T), rs4803779 (T), rs4803780 (C), rs3760625 (G), rs3760626 (A), rs3760627 (T), rs3760628 (G), rs66867801 (C), rs7259679 (C), rs66771331 (G), rs7245611 (T), rs3760629 (A), rs2239375 (T), rs8100120 (T), rs8100236 (T), rs111997200 (T), rs113073220 (DEL), and rs11878597 (T). This block has eight haplotypes, of which four are present in AFR, three in each AMR, and SAS, and two in EAS and EUR. Of all the haplotypes, only the wild-type and the mutant type are observed in all the populations. The most deleterious haplotype is the wild type, which significantly decrease APOE expression, and its higher and lower frequencies are also observed in EUR (54%) and AFR (38%), respectively. Linkage disequilibrium block V is formed by seven variants: rs4803775 (T), rs5120 (T), rs4803776 (T), rs7247551 (G), rs204905 (G), rs35193317 (T), and rs71352247 (T). This block shows seven haplotypes, and the EAS and EUR populations have the greater variability, with frequencies of four of them. Differently of the other blocks, the AFR populations has the lower number of haplotypes of block V, only two of them. The haplotype that causes the larger reduction in APOE expression in the lungs is the V.2. This haplotype is identified in all populations, with higher frequencies in EUR (49,5%) and lower in AFR (19%). Linkage disequilibrium block VI has the largest number of variants, 25: rs150448996 (DEL), rs1130742 (C), rs12709889 (G), rs73047643 (T), rs2238682 (C), rs7252480 (C), rs1882752 (G), rs112704499 (G), rs142534985 (INS), rs2142074 (A), rs11668758 (C), rs11665849 (T), rs11669609 (C), rs2075620 (A), rs56803710 (C), rs7253458 (C), rs55762617 (C), rs55778858 (G), rs60876330 (C), rs11083755 (C), rs2075618 (G), rs35080293 (T), rs892131 (C), rs73047694 (G), and rs7251655 (C). This block is composed of 12 haplotypes, albeit the allele frequency of 10 are rare and only two of them are observed in all populations, the wild and mutant types. The wild haplotype causes the greater reduction in APOE expression, and has the highest frequencies recorded, ranging from 49% in EAS to 72% in SAS. Lastly, the block VII is formed by six variants: rs34449594 (DEL), rs2376868 (A), rs12972222 (A), rs150557566 (DEL), rs9749077 (G), and rs11668285 (A). This block shows 13 haplotypes, where the AFR has the greater variability (containing seven haplotypes) and SAS has the lesser variability (with frequencies of three haplotypes). The wild and mutant haplotypes are the only two that are observed in all populations. Here, the mutant haplotype causes the most impact on APOE expression, decreasing its gene expression in the lungs. This haplotype has a great difference of frequency among the populations, AFR (2%), AMR (23%), EAS (24%), EUR (44%), and SAS (34%). Once again, the Europeans has the highest frequencies while African has the lowest. The pairwise comparison of the mean expression of each linkage disequilibrium blocks showed statistically difference (p < 2e-16). The blocks that are most distinguished in terms of decreased expression of APOE are blocks I and IV in relation to all blocks (p < 0.0001), except among themselves. A close analysis reveals that block V causes the most decrease in APOE expression in lung tissues, with a mean of 0.397, which can be observed in Table 3. Also, it is noteworthy that this block has extremely high frequencies in all evaluated populations (>98%).
Table 3

Pairwise comparison of the LD blocks. For each LD block, the sum of frequencies of haplotypes and the expression of APOE was computed concerning the mean of the median of normalized expression from eQTL results in GTEx portal.

Haplotype BlocksExpression valueAFRAMREASEURSAS
I-0.2070.7670.6010.4620.6760.690
II-0.3780.3880.2930.3320.5210.385
III-0.3740.4490.4140.4200.5530.414
IV-0.3690.4450.4120.4180.5610.396
V-0.3970.9930.9800.9960.9860.989
VI-0.1830.7780.6280.5010.7220.757
VII
-0.360
0.437
0.306
0.275
0.470
0.382
x¯0.6080.5190.4860.6410.573
Pairwise comparison of the LD blocks. For each LD block, the sum of frequencies of haplotypes and the expression of APOE was computed concerning the mean of the median of normalized expression from eQTL results in GTEx portal.

Discussion

The COVID-19 pandemic has infected over 25 million of today people worldwide, 5% of whom evolved to death, which is equivalent to more than 800 thousand of cases [21]. Still according to the Worldometer's COVID-19 data, of the actual active cases, more than 60 thousand are classified as critical or severe. Also, seven of the ten countries with the highest death rates per million are European (San Marino, Belgium, Andorra, Spain, United Kingdom, Italy, and Sweden). To reduce disease burden and improve clinical outcomes of patients affected by COVID-19, it is fundamental to create monitoring strategies to identify those who are most susceptible to developing severe forms of the disease. One of the approaches consider interindividual genetic differences among patients. Following this premise, two large studies of patients with European-ancestry from the UK Biobank (UKB) cohort reported that individuals with APOE ε4∗ε4 genotype had an increase in the risk of developing severe COVID-19 and a four-fold increase in mortality after testing positive for COVID-19 [13,22]. The aim of this study was to shine new light on the influence of APOE genotypes in predicting poor prognosis of COVID-19, such as severity and mortality, through an examination of allelic frequencies of the variants that can alter patterns of this gene expression in lung tissues. We based our findings through publicly available data analysis of the GTEx platform and 1000 Genomes Project database. The evaluation of the 98 expression-modifying variants of the APOE gene formed seven haplotype blocks with considerable levels of variation among the global populations. All the haplotype genotypes, except that from the VI block, that lead to the greatest reduction in APOE expression in lung tissues are more frequent in Europeans (with a mean of 0.507). Otherwise, their lowest frequencies are found in AFR (regarding II, III, IV, V, and VII haplotype blocks; mean of 0.231) and EAS populations (I and VI haplotype groups; mean of 0.465). In vivo experiments models show that ApoE-deficient mice demonstrated greater increases in lung lavage protein levels, neutrophil counts, and cytokine expression than wild-type animals [23, 24]. These studies confirm the role of low levels of APOE expression in modulating inflammation in the setting of acute lung injury, which has been associated to an interleukin-6–dependent mechanism that increases endothelial cell permeability to oxidized LDL [25]. Interestingly, IL-6 is a major cytokine released during the “cytokine storm”, the main responsible for COVID-19 complications, primarily represented by the development of acute respiratory distress syndrome (ARDS) [26]. Together, these findings may explain why individuals of European-ancestry, who have higher frequencies of haplotypes that confer deficiency in APOE expression, may be at higher risk to COVID-19 severe course, as demonstrated by the current available epidemiology. Contrarily, individuals from Africa and East Asia regions, both carrying lower frequencies of expression-modifying haplotypes of APOE, have reported fewer numbers of severe cases and smaller rates of mortality of COVID-19. Conflicting with our hypothesis, some investigations point ApoE as a causative for complications during COVID-19 clinical evolution. The authors sustained that individuals with ate least one copy of APOE ε4 alleles may be more prone to progress to severe illness from SARS-CoV-2 infection due to an exacerbated innate immune response followed by cytokine storm and resulting in ARDS (Moriarty et al. 2020; Goldstein et al. 2020) [27,28]. However, this cannot be proven by our results since the variants that composes the APOE ε4∗ε4 genotype are absent of the GTEx list of variants expressed in lung tissues. ApoE's influence on the clinical aspects of COVID-19 may also be correlated with its intrinsic role in the pathophysiology of obesity. Aguilar and colleagues demonstrated that ApoE −/− mices fed with an obesogenic diet showed a significant increase in atherosclerosis and systemic inflammatory processes [29].Another study showed that the APOE Ɛ2 and Ɛ4 alleles were associated, respectively, with Body Mass Index (BMI) and a higher risk of atherosclerosis [30]. Both processes, atherosclerosis and systemic inflammation, predispose to the development of obesity, showing that variants and protein isoforms of the APOE gene have a direct impact on metabolic disorders. Studies have already shown that obesity can be considered a risk factor for the severity and mortality of Sars-CoV-2 infections [31, 32]. A recent meta-analysis showed that inpatients who have a BMI greater than 30 demonstrate a poor prognosis and higher mortality and severity rates of COVID-19; the authors calculated that the risk for composite poor outcome increased by 5% for every 5 kg/mg2 increase in BMI [33]. The present study indicates a potential genetic contribution of APOE expression-modifying variants in assess poor prognosis of COVID-19, such as severity and mortality outcomes. These findings are in accordance with the higher incidence and mortality rates described in Europeans, who have greater frequencies of haplotypes that alter this gene expression in lungs. Future research is needed to describe these variants in countries that have become the epicenter of the pandemic, such as United States, India, and Brazil, and to validate our findings in cohorts of patients, better elucidating the real role of ApoE to COVID-19 biological mechanisms.

Declarations

Author contribution statement

Juliana Carla Gomes Rodrigues: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper. Pablo Pinto: Analyzed and interpreted the data. Luciana Pereira Colares Leitão, Lui Wallacy Morikawa Souza Vinagre, Natasha Monte: Analyzed and interpreted the data; Wrote the paper. Marianne Rodrigues Fernandes, André Salim Khayat, Paulo Pimentel de Assumpção, Ney Pereira Carneiro dos Santos: Contributed reagents, materials, analysis tools or data. Sidney Emanuel Batista dos Santos: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data.

Funding statement

This work was supported by Fundação Amazônia de Amparo a Estudos e Pesquisa, Universidade Federal do Pará and Pró-reitoria de Pesquisa e Pós-graduação.

Data availability statement

Data included in article/supplementary material/referenced in article.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.
  30 in total

Review 1.  Cell-specific production, secretion, and function of apolipoprotein E.

Authors:  Maaike Kockx; Mathew Traini; Leonard Kritharides
Journal:  J Mol Med (Berl)       Date:  2018-03-07       Impact factor: 4.599

Review 2.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 3.  Beyond the CNS: The many peripheral roles of APOE.

Authors:  Ana B Martínez-Martínez; Elena Torres-Perez; Nicholas Devanney; Raquel Del Moral; Lance A Johnson; Jose M Arbones-Mainar
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

4.  Apolipoprotein E-deficient mice are susceptible to the development of acute lung injury.

Authors:  Cory M Yamashita; Michael B Fessler; Lakshman Vasanthamohan; Joanne Lac; Jennifer Madenspacher; Lynda McCaig; Lijuan Yao; Lefeng Wang; Valeria Puntorieri; Sanjay Mehta; Jim F Lewis; Ruud A W Veldhuizen
Journal:  Respiration       Date:  2014-03-22       Impact factor: 3.580

5.  A Novel Approach to High-Quality Postmortem Tissue Procurement: The GTEx Project.

Authors:  Latarsha J Carithers; Kristin Ardlie; Mary Barcus; Philip A Branton; Angela Britton; Stephen A Buia; Carolyn C Compton; David S DeLuca; Joanne Peter-Demchok; Ellen T Gelfand; Ping Guan; Greg E Korzeniewski; Nicole C Lockhart; Chana A Rabiner; Abhi K Rao; Karna L Robinson; Nancy V Roche; Sherilyn J Sawyer; Ayellet V Segrè; Charles E Shive; Anna M Smith; Leslie H Sobin; Anita H Undale; Kimberly M Valentino; Jim Vaught; Taylor R Young; Helen M Moore
Journal:  Biopreserv Biobank       Date:  2015-10       Impact factor: 2.300

6.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

7.  Human apolipoprotein E promotes hepatitis B virus infection and production.

Authors:  Luhua Qiao; Guangxiang George Luo
Journal:  PLoS Pathog       Date:  2019-08-08       Impact factor: 6.823

Review 8.  The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease.

Authors:  Courtney M Kloske; Donna M Wilcock
Journal:  Front Immunol       Date:  2020-04-30       Impact factor: 7.561

Review 9.  Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.

Authors:  Patrick M Moriarty; Lauryn K Gorby; Erik S Stroes; John P Kastelein; Michael Davidson; Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2020-07-25       Impact factor: 5.113

Review 10.  Obesity: A critical risk factor in the COVID-19 pandemic.

Authors:  See Kwok; Safwaan Adam; Jan Hoong Ho; Zohaib Iqbal; Peter Turkington; Salman Razvi; Carel W Le Roux; Handrean Soran; Akheel A Syed
Journal:  Clin Obes       Date:  2020-08-28
View more
  1 in total

1.  Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach.

Authors:  Theodosia Charitou; Panagiota I Kontou; Ioannis A Tamposis; Georgios A Pavlopoulos; Georgia G Braliou; Pantelis G Bagos
Journal:  Pharmacogenomics J       Date:  2022-09-28       Impact factor: 3.245

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.